Contamination by human and veterinary pharmaceutical derivatives refers to the undesirable presence of drug residues in the environment, including water, soil, and living organisms. This contamination can occur at various stages, including production, consumption, and disposal of medications. Main sources include releases from pharmaceutical facilities, wastewater discharges containing drug residues, and uncontrolled use of veterinary drugs in agriculture.
Pharmaceutical contamination raises environmental and health concerns, impacting ecosystems and posing risks of antibiotic-resistant bacteria emergence. Conventional wastewater treatment methods may not efficiently remove these compounds, contributing to their persistence. Efforts are underway to develop advanced treatment technologies and sustainable pharmaceutical waste management practices. Regulations aim to limit releases and promote environmental monitoring to assess the extent of contamination by pharmaceutical derivatives.

Pharmaceuticals

Contamination by human and veterinary pharmaceutical derivatives refers to the undesirable presence of drug residues in the environment, including water, soil, and living organisms. This contamination can occur at various stages, including production, consumption, and disposal of medications. Main sources include releases from pharmaceutical facilities, wastewater discharges containing drug residues, and uncontrolled use of veterinary drugs in agriculture. Pharmaceutical contamination raises environmental and health concerns, impacting ecosystems and posing risks of antibiotic-resistant bacteria emergence. Conventional wastewater treatment methods may not efficiently remove these compounds, contributing to their persistence. Efforts are underway to develop advanced treatment technologies and sustainable pharmaceutical waste management practices. Regulations aim to limit releases and promote environmental monitoring to assess the extent of contamination by pharmaceutical derivatives.

FELYPRESSIN CRS (0.994 MG)

FELYPRESSIN CRS (0.994 MG)

56-59-7

DISCOVER
RANITIDINE IMPURITY J CRS (0.0003 MG)

RANITIDINE IMPURITY J CRS (0.0003 MG)

NA

DISCOVER
PENTAZOCINE LACTATE - REFERENCE SPECTRUM (N/A)

PENTAZOCINE LACTATE - REFERENCE SPECTRUM (N/A)

NA

DISCOVER
METHYLROSANILINIUM CHLORIDE CRS (40 MG)

METHYLROSANILINIUM CHLORIDE CRS (40 MG)

548-62-9

DISCOVER
FLUDARABINE PHOSPHATE CRS (120 MG)

FLUDARABINE PHOSPHATE CRS (120 MG)

75607-67-9

DISCOVER
CEFOTAXIME ACID CRS (20 MG)

CEFOTAXIME ACID CRS (20 MG)

63527-52-6

DISCOVER
STAVUDINE FOR SYSTEM SUITABILITY CRS (10 MG)

STAVUDINE FOR SYSTEM SUITABILITY CRS (10 MG)

3056-17-5

DISCOVER
SALMETEROL XINAFOATE CRS (70 MG)

SALMETEROL XINAFOATE CRS (70 MG)

94749-08-3

DISCOVER
SALMETEROL XINAFOATE FOR SYSTEM SUITABILITY CRS (6.105 MG)

SALMETEROL XINAFOATE FOR SYSTEM SUITABILITY CRS (6.105 MG)

94749-08-3

DISCOVER
ATRACURIUM BESILATE CRS (120 MG)

ATRACURIUM BESILATE CRS (120 MG)

64228-81-5

DISCOVER
LAMIVUDINE CRS (150 MG)

LAMIVUDINE CRS (150 MG)

134678-17-4

DISCOVER
LAMIVUDINE FOR SYSTEM SUITABILITY 2 CRS (10.3 MG)

LAMIVUDINE FOR SYSTEM SUITABILITY 2 CRS (10.3 MG)

NA

DISCOVER